Developing new drugs to inhibit cancer cell growth

Multidisciplinary Investigation of Antitubulin Heterocycles using Synthesis, Biology, and Structural Analysis

NIH-funded research Hobart and William Smith Colleges · NIH-10729604

This study is working on new medicines that target a protein important for cancer cells to grow and survive, with the hope that these new treatments will be safer and more effective for patients than what we have now.

Quick facts

Grant typeR15 grant
Study typeNIH-funded research
Funding institutionHobart and William Smith Colleges NIH-funded
Lab location1 site (Geneva, United States)
Project IDNIH-10729604 on NIH RePORTER

What this research studies

This research focuses on creating new drugs that target tubulin, a protein essential for cancer cell division and structure. By using a method called rational drug design, the team aims to develop novel compounds that can effectively inhibit tubulin polymerization, which is crucial for cancer cell survival. The research involves synthesizing new drug candidates and testing their effectiveness and safety against cancer cells. Patients may benefit from these new treatments that could potentially overcome the limitations of current cancer therapies.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from new therapeutic options.

Not a fit: Patients who are not currently undergoing cancer treatment or those with non-malignant conditions may not receive any benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective and less toxic cancer treatments.

How similar studies have performed: Previous research has shown promise in developing tubulin inhibitors, indicating that this approach has potential for success.

Where this research is happening

Geneva, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions American Cancer SocietyAnti-Cancer AgentsCancer DrugNeoplastic Disease Chemotherapeutic Agentsanti-cancer drug
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.